Sodium phenylbutyrate - Access Pharmaceuticals

Drug Profile

Sodium phenylbutyrate - Access Pharmaceuticals

Alternative Names: EL 532; Phenylbutyrate - Access; VP 101; VP 1301

Latest Information Update: 05 May 2011

Price : $50

At a glance

  • Originator Virium Pharmaceuticals
  • Developer Access Pharmaceuticals
  • Class Antineoplastics; Electrolytes; Phenylbutyrates; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma

Highest Development Phases

  • Discontinued Colorectal cancer; Glioblastoma; Haematological malignancies; Prostate cancer; Radiation-induced skin damage

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 31 Mar 2011 Discontinued - Phase-II for Colorectal cancer in USA (IV)
  • 31 Mar 2011 Discontinued - Phase-II for Colorectal cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top